Founded in 2020, Priothera is a Franco-Irish biotechnology company based in Saint-Louis with 25 employees. Its lead asset is mocravimod, an oral sphingosine-1-phosphate receptor modulator now advancing toward a Phase 3 clinical trial for the treatment of hematological malignancies. The company’s goal is to commercialize mocravimod by 2030 and establish it as a standard-of-care in blood cancer therapy. Priothera has already secured €63 million in funding since inception to support clinical development. To propel the Phase 3 program, it has initiated additional fundraising efforts, including a €3 million crowdfunding campaign on Wiseed and a broader €40 million Series B round. The firm recently bolstered its non-dilutive financing with a €1.70 million i-Nov 2025 grant from Bpifrance and €685,000 from the Région Grand Est through the European Regional Development Fund. These funds are intended to accelerate international clinical trials and expand the company’s development pipeline.

Total raised

$59M

Funding rounds

3

Latest round

Equity

Latest activity

Sep 2025